ETF Series Solutions Trust Range Cancer Therapeutics ETF
CNCR
CNCR was delisted on the 27th of May, 2025.
20 hedge funds and large institutions have $8.89M invested in ETF Series Solutions Trust Range Cancer Therapeutics ETF in 2019 Q2 according to their latest regulatory filings, with 3 funds opening new positions, 7 increasing their positions, 5 reducing their positions, and 4 closing their positions.
40% more repeat investments, than reductions
Existing positions increased: 7 | Existing positions reduced: 5
6% more capital invested
Capital invested by funds: $8.41M → $8.89M (+$481K)
2.33% more ownership
Funds ownership: 21.07% → 23.4% (+2.3%)
5% less funds holding
Funds holding: 21 → 20 (-1)
25% less first-time investments, than exits
New positions opened: 3 | Existing positions closed: 4
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
SWM
SeaCrest Wealth Management
Purchase,
New York
|
+$375K |
| 2 |
Royal Bank of Canada
Toronto,
Ontario, Canada
|
+$355K |
| 3 |
Jane Street
New York
|
+$339K |
| 4 |
BL
BCWM LLC
Overland Park,
Kansas
|
+$136K |
| 5 |
Citigroup
New York
|
+$80.3K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Susquehanna International Group
Bala Cynwyd,
Pennsylvania
|
-$377K |
| 2 |
OC
Oppenheimer & Co
New York
|
-$215K |
| 3 |
LPL Financial
San Diego,
California
|
-$194K |
| 4 |
BWA
BDO Wealth Advisors
Jacksonville,
Florida
|
-$67.6K |
| 5 |
UBS Group
Zurich,
Switzerland
|
-$49K |
CNCR Hedge Fund Activity: Q2 2019 in Review
20 of the 4,625 institutional investors tracked by Wall St. Rank reported a position in ETF Series Solutions Trust Range Cancer Therapeutics ETF (CNCR) for Q2 2019, worth a combined $8.89M — up 5.7% from $8.41M a quarter earlier.
Sellers outnumbered buyers: 4 funds closed out of CNCR and 3 opened new positions — a net loss of 1 holder — while 5 trimmed existing stakes and 7 added.
The largest buyer was SeaCrest Wealth Management, adding an estimated $375K. The largest seller was Susquehanna International Group, exiting entirely with an estimated $377K sold.
- 20 institutional investors held ETF Series Solutions Trust Range Cancer Therapeutics ETF (CNCR) as of Q2 2019, down from 21 in Q1 2019.
- Funds reported $8.89M of ETF Series Solutions Trust Range Cancer Therapeutics ETF stock for Q2 2019, up 5.7% quarter-over-quarter.
- 3 funds opened new ETF Series Solutions Trust Range Cancer Therapeutics ETF positions in Q2 2019 and 4 closed out, a net change of -1 holder.
- The largest ETF Series Solutions Trust Range Cancer Therapeutics ETF buyer in Q2 2019 was SeaCrest Wealth Management, an estimated $375K added.
- The largest ETF Series Solutions Trust Range Cancer Therapeutics ETF seller in Q2 2019 was Susquehanna International Group, an estimated $377K sold.
Based on aggregated 13F filings for Q2 2019.